A new global study reveals that an immunotherapy drug called teplizumab can delay the onset of Type 1 diabetes for at least two years in high-risk kids and adults, according to the results of a recent study with 28 research sites. Recently reported in WNDU 16...
The MD Coastal Dispatch report that that Operation Shooting Star (OSS), an autoimmune disease Advocacy organization, partnered with a leader in autoimmune disease research, Benaroya Research Institute (BRI) at Virginia Mason.
TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.
159 WEST BROADWAY SUITE 200 SALT LAKE CITY, UT 84101
Pin It on Pinterest